Alumis INC Form 4 insider transactions

Alumis Inc. and ACELYRIN, Inc. have announced a definitive agreement for an all-stock merger, aiming to create a well-capitalized biopharmaceutical company focused on immune-mediated diseases with a cash runway into 2027.

Alumis and ACELYRIN have amended their merger agreement, granting ACELYRIN stockholders approximately 48% ownership in the combined company following the merger's completion.

Alumis and ACELYRIN have amended their merger agreement, adjusting the stock exchange ratio to reflect current market conditions and investor expectations.

Alumis and ACELYRIN have amended their merger agreement, increasing the ownership stake for ACELYRIN stockholders in the combined company to approximately 48% on a fully diluted basis.

Alumis and ACELYRIN have jointly filed a definitive proxy statement/prospectus regarding their proposed merger, with stockholders set to vote on the transaction at special meetings in May 2025.

Director Alan Colowick increased his holdings in Alumis Inc. through purchases made via a revocable living trust.

Alumis Inc.'s CEO, Martin Babler, purchased 15,650 shares of common stock at a weighted-average price of $6.4366 on April 1, 2025.

Alumis and Kaken Pharmaceutical Co., Ltd. have entered into a collaboration and license agreement for ESK-001 in Japan, securing a key market and extending Alumis' cash runway.

Alumis Inc. announces a merger agreement with ACELYRIN, along with its year-end 2024 financial results and clinical development updates.

Alumis Inc. and ACELYRIN, Inc. have announced a definitive merger agreement to create a leading immunology and inflammation (I&I) company with a diversified pipeline and extended cash runway.

Alumis and ACELYRIN have announced a merger agreement to create a well-capitalized, late-stage clinical biopharmaceutical company focused on developing and commercializing transformative therapies for immune-mediated diseases.

Alumis Inc. and ACELYRIN, Inc. have announced a definitive agreement for an all-stock merger, aiming to create a well-capitalized, late-stage clinical biopharmaceutical company focused on immune-mediated diseases.

Alumis and ACELYRIN reaffirm their commitment to merge in an all-stock transaction, creating a leading clinical-stage biopharma company focused on immune-mediated diseases.

Roy C. Hardiman, Chief Business & Strategy Officer of Alumis Inc., reports the acquisition of stock options.

Derrick Richardson, SVP of People and Culture at Alumis Inc., reports the acquisition of 50,000 stock options with an exercise price of $5.06.

Alumis Inc.'s Chief Financial Officer, John R. Schroer, reported the acquisition of stock options in the company.

Mark Christopher Bradley, Chief Development Officer at Alumis Inc., acquired stock options for 140,000 shares at an exercise price of $5.06 on February 18, 2025.

Alumis Inc.'s Chief Legal Officer, Sara Klein, reports the acquisition of stock options in the company.

Chief Medical Officer of Alumis Inc., Jorn Drappa, reports acquisition of stock options.

David M. Goldstein, Chief Scientific Officer of Alumis Inc., reports the acquisition of stock options and updates to his beneficial ownership of company stock.

Alumis Inc.'s President, CEO, and Chairman, Martin Babler, reports the acquisition of 523,000 stock options with an exercise price of $5.06.

Alumis and ACELYRIN are merging in an all-stock transaction to create a combined company with a diversified late-stage immunology pipeline and stronger financial resources.

Alumis Inc. and ACELYRIN, Inc. have announced a definitive merger agreement, subject to stockholder and regulatory approvals, with the goal of creating a stronger combined entity.

Alumis and ACELYRIN have announced a merger, creating a combined entity with approximately $737 million in cash to fund operations into 2027 and advance their respective clinical programs.

Alumis and ACELYRIN are merging in an all-stock transaction to create a late-stage clinical biopharma company focused on immune-mediated diseases.

Srinivas Akkaraju, a director at Alumis Inc., filed an amended Form 4 to include the purchase of shares by Samsara BioCapital, L.P. in the company's initial public offering.

Foresite Labs and related entities report changes in beneficial ownership of Alumis Inc. common stock following the conversion of preferred stock in connection with the company's initial public offering.

Foresite Capital and related entities report the conversion of preferred stock to common stock and acquisition of additional shares in Alumis Inc. following its initial public offering.

Director James B. Tananbaum reports changes in beneficial ownership of Alumis Inc. common stock and convertible preferred stock following the company's initial public offering.

AyurMaya Capital Management reports changes in beneficial ownership of Alumis Inc. stock following the company's initial public offering, including conversion of preferred stock to common stock.